Adagene(ADAG)
JIANGSU, ChinaBiotechnology
Focus: Adagene is a China-based biotechnology company specializing in antibody discovery and engineering focused on oncology, publicly traded on NASDAQ (ADAG). The company operates an early-stage pipeline with Phase 1/2 programs in solid tumors and advanced liver cancers.
Profile data last refreshed 18h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Adagene
AI assessmentNot HiringNo open roles listed right now. Follow Adagene to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Adagene's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Phase 1
Clinical Trials (1)
NCT05614258Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
Phase 1Help build intelligence for Adagene
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.